Nigrostriatal lesions alter oral dyskinesia and c-Fos expression induced by the serotonin agonist 1-(m-chlorophenyl)piperazine in adult rats

Journal of Neuroscience

Volumn 20, Issue 13, 2000, Pages 5170-5178

  De Deurwaerdère, Philippe ^a   Chesselet, Marie Françoise ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Basal ganglia; c Fos; Dopamine; Dyskinesia; m CPP; Parkinson's disease; Serotonin; Serotonin 2C receptors

Indexed keywords

DOPAMINE; PIPERAZINE; SEROTONIN; SEROTONIN 2C RECEPTOR; SEROTONIN AGONIST;

ANIMAL EXPERIMENT; ARTICLE; BASAL GANGLION; DOPAMINE BLOOD LEVEL; DYSKINESIA; GENE EXPRESSION; MALE; NEUROTRANSMISSION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; ONCOGENE C FOS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SEROTONIN BLOOD LEVEL;

EID: 0034235165     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.20-13-05170.2000     Document Type: Article

References (54)

1. Azmitia EC, Segal M (1978) An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. J Comp Neurol 179:641-668.
2. Barnes NM, Sharp T (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38:1083-1152.
3. Boraud T, Bezard E, Guehl D, Bioulac B, Gross C (1998) Effects of L-DOPA on neuronal activity of the globus pallidus externalis (GPe) and globus pallidus internalis (GPi) in the MPTP-treated monkey. Brain Res 787:157-160.
4. Brotchie P, lansek R, Horne MK (1991) Motor function of the monkey globus pallidus. II. Cognitive aspects of movement and phasic neuronal activity. Brain 114:1685-1670.
5. Chase TN, Engber TM, Mouradian MM (1994) Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson disease. Neurology 44:S15-S18.
6. Chesselet M-F (2000)) Dopamine-GABA interactions In: Handbook of experimental pharmacology. (Di Chiara G, ed). Heidelberg: Springer.
7. 2C receptor protein in the rat CNS Neuropharmacology 39:123-132.
8. Cook DF, Wirtshafter D (1995) Serotonin agonist-induced c-fos expression in the rat striatum. Soc Neurosci Abstr 21:1424.
9. Cook DF, Wirtshafter D (1998) Quinpirole attenuates striatal c-fos induction by 5-HT, opioid and muscurinic receptor agonists. Eur J Pharmacol 349:41-47.
10. 2C receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation. J Neurochem 73:1033-1042.
11. De Deurwaerdère P, Bonhomme N, Le Moal M, Spampinato U (1995) D-Fenfluramine increases striatal extracellular dopamine in vivo independently of serotonergic terminals or dopamine uptake sites. J Neurochem 65:1100-1108.
12. Delfs JM, Ciarumitaro VM, Parry T, Chesselet M-F (1995) Subthalamic nucleus lesions: widespread effects on changes in gene expression induced by nigrostriatal dopamine depletion in rats. J Neurosci 15:6562-6575.
13. DeLong MR (1990) Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13:281-285.
14. 2C-2B receptor agonists: a combined in vivo electrophysiological and microdialysis study. Synapse 35:53-61.
15. Dogali M, Fazzani E, Kolodny E, Eidelberg D, Sterio D, Devinski O, Berie A (1995) Stereotaxic ventral pallidotomy for Parkinson's disease. Neurology 45:753-761.
16. Ebabi M, Srinivasan SK ( 1995) Pathogenesis, prevention, and treatment of neuroleptic-induced movement disorders. Pharmacol Rev 47:575-604.
17. 2C-induced oral dyskinesia. Neuroscience 72:117-128.
18. 2C receptor messenger RNA in the basal ganglia of adults rats. J Comp Neurol 384:233-247.
19. El Mansari M, Radja F, Ferron A, Reader TA, Molina-Holgado E, Descarries L (1994) Hypersensivity to serotonin and its agonists in serotonin-hyperinnervated neostriatum after neonatal dopamine denervation. Eur J Pharmacol 261:171-178.
20. Eriksson E, Engberg G, Bing O, Nissbrandt H (1999) Effects of mCPP on the extracellular concentrations of serotonin and dopamine in rat brain. Neuropsychopharmacology 20:287-296.
21. Ferré S, Cortés R, Artigas F (1994) Dopaminergic regulation of the serotonergic raphe-striatal pathway: microdialysis studies in freely moving rats. J Neurosci 14:4839-4846.
22. 2C receptor antagonism in the substantia nigra pars reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp Neurol 151:35-49.
23. Gerfen CR, Herkenham M, Thibault J (1987) The neostriatal mosaïc. II. Patch-and matrix-directed mesostriatal dopaminergic and nondopaminergic systems. J Neurosci 7:3915-3934.
24. Gong L, Kostrzewa RM (1992) Supersensitizcd oral response to a serotonin agonist in neonatal 6-OHDA-treatcd rats. Pharmacol Biochem Behav 41:621-623.
25. Gong L, Kostrzewa RM, Fuller RW, Perry K W (1992) Supersensitization of oral response to SKF 38393 in neonatal 6-OHDA-lesioned rats is mediated through a serotonine system. J Pharmacol Exp Ther 261:1000-1007.
26. Ikeguchi K, Kuroda A (1995) Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs. Eur Arch Psychiatry Clin Neurosci 244:320-324.
27. Kahn RS, Wetzler S (1991) m-Chlorophenylpiperazine as a probe of serotonin receptors. Biological Psychiatry 30:1139-1166.
28. Kostrzewa RM, Reader TA, Descarries L (1998) Serotonin neural adaptations to ontogenic loss dopamine neurons in rat brain. J Neurochem 70:889-898.
29. Lang AE, Duff J, Saint-Cyr JA, Trepanier L, Gross RE, Lombardi W, Montgomery E, Hutchinson W, Lozano AM (1999) Posteroventral pallidotomy in Parkinson's disease. J Ncurol 246:II/28-II/41.
30. Leslie RA, Moorman JM, Coulson A, Grahame-Smith DG (1993) Serotonin2/lC receptor activation causes a localized expression of the immediate-early gene c-fos in rat brain: evidence for involvement of dorsal raphe nucleus projection fibres. Neuroscience 53:457-463.
31. Mehta A, Thermos K, Chesselet M-F (2000) Increased behavioral response to dopaminergic stimulation of the subthalamic nucleus after nigrostriatal lesions. Synapse, in press.
32. Melamed E, Zoldan J, Friedberg G, Ziv I, Weizmann A (1996) Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy. Adv Neurol 69:545-550.
33. Meltzer HY, Nash JF (1991) Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 43:587-604.
34. 2A/2C-receptor function. Neuroscience 72:129-139.
35. Ng LKY, Chase TN, Colburn RW, Kopin IJ (1972) L-DOPA in parkinsonism: a possible mechanism of action. Neurology 22:688-696.
36. Numan S, Lundgren KH, Wright DE, Herman JP, Seroogy KB (1995) Increased expression of 5-HT2 receptor mRNA in rat striatum following 6-OHDA lesions of the adult nigrostriatal pathway. Mol Brain Res 29:391-396.
37. Pact V, Giduz T (1999) Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskincsias. Neurology 53:1154.
38. Parry TJ, Eberle-Wang K, Lucki I, Chesselet M-F (1994) Dopaminergic stimulation of subthalamic nucleus elicits oral dyskinesia in rats. Exp Neurol 128:181-190.
39. Pasqualetti M, Ori M, Castagna M, Marazziti D, Cassano GB, Nardi I (1999) Distribution and cellular localization of the serotonin type 2C receptor messenger RNA in human brain. Neuroscicncc 92:601-611.
40. Paxinos G, Watson C ( 1986) The rat brain in stereotaxic coordinates, Ed 2. Sydney: Academic.
41. Pazos A, Cortes R, Palacios JM (1985) Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res 346:231-249.
42. Plech A, Brus R, Kalbfleisch JH, Kostrzewa RM (1995) Enhanced oral activity responses to intrastriatal SKF 38393 and m-CCP arc attenuated by intrastriatal mianscrin in neonatal 6-OHDA-lesionned rats. Psychopharmacology 119:466-473.
43. Rick CE, Stanford IM, Lacey MG (1995) Excitation of rat substantia nigra pars reticulata neurons by 5-hydroxytryptamine in vitro: evidence for a direct action mediated by 5-hydroxytryptamine2C receptors. Neuroscience 69:903-913.
44. Roth BL, Ciaranello RD, Meltzer HY (1992) Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors. J Pharmacol Exp Ther 260:1361-1365.
45. Rouillard C, Bovelto S, Gervais J, Richard D (1996) Fenfluramine-induccd activation of the immediate-early gene c-fos in the striatum: possible interaction between serotonin and dopamine. Mol Brain Res 37:105-115.
46. Salamone JD, Johnson CJ, McCullough LD, Steinpreis RE (1990) Lateral striatal cholinergic mechanisms involved in oral motor activities in the rat. Psychopharmacology 85:71-79.
47. 2C receptor function in caudate. 28th Annual Meeting of Society for Neuroscience. Los Angeles, CA, November.
48. Sgambato V, Abo V, Rogard M, Besson MJ, Deniau JM (1997) Effect of electrical stimulation of the cerebral cortcx on the expression of the Fos protein in the basal ganglia. Neuroscience 81:93-112.
49. Stewart BR, Jenner P, Marsden CD (1989) Induction of purposeless chewing behavior in rats by 5-HT agonists drugs. Eur J Pharmacol 162:101-107.
50. Sutton JP, Coudwell W, Lew MF, Mallory L, Grafton S. DeGiorgio C, Welsh M, Apuzzo MLJ, Ahmadi J, Waters CH (1995) Ventroposterior medial pallidotomy in patients with advanced Parkinson's disease. Neurosurgery 36:1112-1117.
51. Tarsy D, Baidessarini RJ (1984) Tardive dyskincsia. Annu Rev Med 35:605-623.
52. Thorrr K, Sarre S, Smolders I. Ebinger G, Michotte Y (1998) Dopaminergic regulation of serotonin release in the substantia nigra of the freely moving rat using microdialysis. Brain Res 796:107-116.
53. Trent F, Teppcr JM (1991) Dorsal raphé stimulation modifies striatalcvoked antidromic invasion of nigral dopaminergic neurons in vivo. Exp Brain Res 84:620-630.
54. Wirtshafter D, Asin KE (1995) Dopamine antagonists induce fos-likcimmunorcactivity in the substantia nigra and entopeduncular nucleus of the rat. Brain Res 670:205-214.